Alkermes to Present Preclinical Data on Novel Selective Effector Cell Activator (SECA™) Immuno-Oncology Candidate at Upcomi...
April 13 2015 - 7:00AM
Business Wire
— Company Plans to Initiate Clinical
Development of Immuno-Oncology Candidate in Third Quarter 2015
—
Alkermes plc (NASDAQ: ALKS) today announced that preclinical
data from studies of the company’s selective effector cell
activator (SECA™) immuno-oncology drug candidate, RDB 1450
(formerly referred to as RDB 1419), will be presented at the
American Association for Cancer Research (AACR) Annual Meeting in
Philadelphia, Pa., April 18-22, 2015. Based on the preclinical data
for this program to date, Alkermes plans to initiate a phase 1
clinical study of RDB 1450 in the third quarter of 2015.
The poster presentations at AACR on Alkermes’ SECA
immuno-oncology program include:
Tuesday, April 21, 2015, 8:00 a.m. – 12:00
p.m. EDT
- “Ex Vivo Expansion and Activation of
Human Lymphocytes With a Selective Agonist of the
Intermediate-Affinity IL-2 Receptor.” Abstract Number: 3158,
Location: Poster Section 12.
Tuesday, April 21, 2015, 1:00 p.m. – 5:00
p.m. EDT
- “Utilizing a Selective Agonist of the
Intermediate-Affinity IL-2 Receptor With an Improved
Pharmacokinetic Profile Leads to an Enhanced Immunostimulatory
Response With Reduced Toxicity in Mice.” Abstract Number: 4280,
Location: Poster Section 24.
- “Determination of the Relative Potency
of a Selective Agonist of the Intermediate-Affinity IL-2 Receptor
on Lymphocytes from Human, Cynomolgus Monkey and Mouse.” Abstract
Number: 4281, Location: Poster Section 24.
For more information, please visit the AACR website at
www.aacr.org.
About the SECA™ Immuno-Oncology
Program
Alkermes’ selective effector cell activator (SECA™) proteins are
designed to harness a patient’s immune system to preferentially
activate and increase the number of tumor killing immune cells.
SECA proteins are selectively targeted to avoid expansion of immune
regulatory cells which interfere with the anti-tumor response. SECA
molecules are engineered using Alkermes’ proprietary PICASSOTM
circular permutation technology leveraging human protein biology to
achieve their unique mechanism of action.
About Alkermes
Alkermes plc is a fully integrated, global
biopharmaceutical company developing innovative medicines for the
treatment of central nervous system (CNS) diseases. The company has
a diversified commercial product portfolio and a substantial
clinical pipeline of product candidates for chronic diseases that
include schizophrenia, depression, addiction and multiple
sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an
R&D center in Waltham, Massachusetts; a research and
manufacturing facility in Athlone, Ireland; and a manufacturing
facility in Wilmington, Ohio. For more information, please visit
Alkermes’ website at www.alkermes.com.
Note Regarding Forward-Looking
Statements
Certain statements set forth in this press release constitute
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended, including,
but not limited to, statements concerning the therapeutic value of
and clinical development plans for our immuno-oncology drug
candidate RDB 1450. You are cautioned that forward-looking
statements are inherently uncertain. Although the company believes
that such statements are based on reasonable assumptions within the
bounds of its knowledge of its business and operations, the
forward-looking statements are neither promises nor guarantees and
are subject to a variety of risks and uncertainties, many of which
are beyond the company’s control, which could cause actual results
to differ materially from those expressed or implied in the
forward-looking statements. These risks and uncertainties include,
among others, whether preclinical and clinical results for the
immuno-oncology drug candidate RDB 1450 will be predictive of
future clinical study results; whether the immuno-oncology drug
candidate RDB 1450 could be shown to be unsafe or ineffective;
whether future clinical trials for the immuno-oncology drug
candidate RDB 1450 will be initiated on time or at all; and those
risks described in the Alkermes plc Annual Report on Form 10-K for
the fiscal year ended Dec. 31, 2014 and in any other subsequent
filings made by the company with the U.S. Securities and Exchange
Commission (SEC), which are available on the SEC’s website at
www.sec.gov. The information contained in this press release is
provided by the company as of the date hereof, and, except as
required by law, the company disclaims any intention or
responsibility for updating or revising any forward-looking
information contained in this press release.
PICASSO™ and SECA™ are trademarks of Alkermes, Inc.
Alkermes Contacts:For
Investors:Rebecca Peterson, +1 781-609-6378orFor Media:Jennifer
Snyder, +1 781-609-6166
Alkermes (NASDAQ:ALKS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alkermes (NASDAQ:ALKS)
Historical Stock Chart
From Apr 2023 to Apr 2024